Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of atezolizumab in PD-L1-positive advanced non-small cell lung cancer
NL-OMON44922Phase 2Recruiting
- Sponsor
- Roche
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Roche. Primary endpoint: Objective response rate per modified RECIST. Started Dec 2017; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44922.